The Texas Medical Center is taking a step forward in cancer prevention and treatment thanks to a multimillion-dollar grant from a Texas organization.

Last month, the Cancer Prevention and Research Institute of Texas announced 71 new statewide grants that totaled $136 million. TMC was the recipient of a $5 million grant that is being used to develop a new accelerator geared at designing new cancer therapeutics treatments.

"Texas Medical Center is proud to be among the esteemed organizations chosen by the CPRIT from across the State of Texas that have been targeted to continue to take the fight to the front lines when it comes to cancer and its deleterious effects on patients and their loved ones," says TMC CEO and president, Bill McKeon, in a release.

TMC | ACT, which stands for Accelerating Cancer Therapeutics, will be a nine-month program of biotech entrepreneurship training and drug development.

"This funding will be critical to the success of our newly formed TMC | ACT program, which will unite business, pharmaceutical, and academic leaders from across the country with the world's largest medical city in order to accelerate the translation of cancer breakthroughs into new drugs that will help save the lives of an untold number of cancer patients," McKeon continues in the release.

The program will bring together startups and researchers for training and mentoring for lessons in market research, FDA regulation, intellectual property, licensing, fundraising, and more. According to the release, the program will conclude with at least one grant and a venture capital pitch day.

This is the second new program TMC has launched this year; TMCalpha was announced in June at the TMCx pitch event. This new program is also geared at connecting research and commercialization and hosts regular events for TMC staff members who have early-stage medical technology ideas.